Lyell Immunopharma (LYEL) Non Operating Income (2021 - 2026)

Lyell Immunopharma (LYEL) has 6 years of Non Operating Income data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 57.58% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (down 53.43% YoY), and the FY2025 full-year result was $13.1 million, down 17.01% from the prior year.
• Non Operating Income fell to $2.2 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $6.6 million in Q3 2023 to a low of -$5.1 million in Q1 2024.
• A 5-year average of $2.5 million and a median of $3.3 million in 2025 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 1351.59% in 2022, while the deepest fall reached 1434.62% in 2022.
• Tracing LYEL's Non Operating Income over 5 years: stood at $6.4 million in 2022, then climbed by 2.99% to $6.6 million in 2023, then slumped by 151.49% to -$3.4 million in 2024, then surged by 179.01% to $2.7 million in 2025, then slipped by 18.01% to $2.2 million in 2026.
• Business Quant data shows LYEL's Non Operating Income at $2.2 million in Q1 2026, $2.7 million in Q4 2025, and -$1.6 million in Q3 2025.